Trevi Therapeutics (TRVI) Accumulated Expenses (2018 - 2026)

Trevi Therapeutics has reported Accumulated Expenses for 9 years, with the latest figure at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 19.57% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $1.3 million (up 19.57% YoY), and the FY2025 full-year result was $2.7 million, down 59.68% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $1.3 million, down from $2.7 million in the prior quarter.
• The five-year high for Accumulated Expenses was $6.8 million in Q4 2024, with the low at $495000.0 in Q1 2022.
• Average Accumulated Expenses over 5 years is $2.2 million, with a median of $1.8 million recorded in 2024.
• Year-over-year, Accumulated Expenses plunged 87.13% in 2022 and surged 359.87% in 2024.
• Tracing TRVI's Accumulated Expenses over 5 years: stood at $1.5 million in 2022, then surged by 145.95% to $3.7 million in 2023, then soared by 83.61% to $6.8 million in 2024, then sank by 59.68% to $2.7 million in 2025, then tumbled by 53.5% to $1.3 million in 2026.
• The last three Accumulated Expenses figures came in at $1.3 million (Q1 2026), $2.7 million (Q4 2025), and $2.4 million (Q3 2025), per Business Quant data.

Peer Comparison